Sohail Tavazoie, MD, PhD
New York, New York
Leon Hess Professor
Head, Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology
Director, Black Family Metastasis Center
Senior Attending Physician
The Rockefeller University
Attending Physician, Memorial Sloan-Kettering Cancer Center
New York, New York
Developing a minimally invasive blood test that can detect and classify breast cancer and predict response to treatment and the likelihood of metastasis.
Mammography is the gold standard for breast cancer screening but does not distinguish between a benign mass and one that is malignant. Invasive biopsy is then needed to analyze the tissue to determine the presence or extent of breast cancer. Traditional biopsy is painful, time-consuming, and only gives a snapshot of the disease in a specific area at a moment in time. Major progress has been made in developing techniques that can detect tumor biomarkers among molecules from normal cells, including liquid biopsy, a minimally invasive diagnostic and monitoring tool that tests a fluid, typically blood, for tumor biomarkers. Liquid biopsy has the potential to identify breast cancer in its earliest stages, before a lump or tumor could be discovered, and in later stages, to monitor how the cancer is responding to therapy in real time.
Drs. Tavazoie and Comen are working to identify specific pieces of tumor genetic material that circulate in the blood and can be used as predictive biomarkers to augment mammography when a suspicious lesion is found, predict the likelihood of a breast cancer to metastasize, or monitor response to therapy. This year, Drs. Tavazoie and Comen recruited 50 more patients on their trial and are using the data collected thus far to develop and train a machine learning algorithm that can distinguish breast cancer from benign breast disease and metastatic disease from localized breast cancer.
Drs. Tavazoie and Comen will continue their work to validate the diagnostic and prognostic value of circulating breast cancer biomarkers and refine their algorithm with current data, as well as identify other types of breast cancer biomarkers in the blood.
“Because of BCRF and this collaboration, we have pushed ourselves to undertake an impactful project that I could not have imagined.” – Dr. Tavazoie
Sohail Tavazoie graduated from the University of California at Berkeley and completed an MD-PhD program at Harvard-MIT, followed by residency training in Internal Medicine at Brigham & Women's Hospital at Harvard and medical oncology and postdoctoral fellowship training at Memorial Sloan Kettering Cancer Center. In 2009, he was recruited to The Rockefeller University as Head of the Laboratory of Systems Cancer Biology. In addition to his laboratory work, Dr. Tavazoie is an attending medical oncologist at Memorial Sloan Kettering Cancer Center.
His laboratory studies the roles that small-RNAs play in regulating cancer metastasis. Small-RNAs, also called microRNAs, have the ability to block the expression of genes. During his postdoctoral work in Joan Massague’s laboratory at MSKCC, Dr. Tavazoie discovered the first set of non-coding RNAs that act as suppressors of metastasis. These small RNAs were found to be shut off in breast tumors of patients that metastasized. His lab at The Rockefeller University has shown that each of these small-RNAs block the expression of distinct sets of genes that enable breast cancer cells to metastasize. These genes were found to enhance the invasive capacity of breast cancer cells as well as their ability to recruit endothelial cells. His laboratory studies the mechanisms by which these small-RNAs and the genes they regulate control metastasis. By better understanding the molecular pathways that govern metastatic progression, he hopes to enable the development of novel therapeutics that prevent the formation and progression of breast cancer metastasis.
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.